FibroBiologics to Provide Company Update at Upcoming Conferences
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
09
Gio, Mag

FibroBiologics to Provide Company Update at Upcoming Conferences

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

(Adnkronos) - HOUSTON, Sept. 14, 2023 /PRNewswire/ -- FibroBiologics, a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today that Pete O'Heeron, Founder/Chief Executive Officer, and Hamid Khoja Ph.D., Chief

Scientific Officer, will be giving company presentations at the upcoming Life Science Intelligence (LSI) Europe '23 Emerging MedTech Summit September 18-22, 2023; and Cell & Gene Meeting on the Mesa October 10-12, 2023. 

Details for the upcoming conference presentations are as follows: 

LSI Europe '23 Emerging MedTech Summit (Barcelona, September 18-22) 

Cell & Gene Meeting on the Mesa (Carlsbad, California. October 10-12) 

"Our presence at these conferences illustrates our commitment to staying at the forefront of developing innovative approaches to treatment of chronic diseases, sharing insights, and fostering collaborations with academia and the biotech community that will drive progress and shape the future," said Pete O'Heeron. "These two conferences provide us with the opportunity to showcase the recent strides and achievements of FibroBiologics in advancing our fibroblast cell-based treatments." 

About FibroBiologicsBased in Houston, FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com. 

General Inquiries:Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.  

Investor Relations:Nic Johnson or Harrison Seidner, Ph.D.Russo Partners(646) Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.  

Media Contact:Liz PhillipsRusso Partners(347) Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.  

Photo - https://mma.prnewswire.com/media/1588787/FibroBiologics_Pete_OHeeron_Headshot.jpgLogo - https://mma.prnewswire.com/media/1588786/FibroBiologics_Logo.jpg  

View original content:https://www.prnewswire.co.uk/news-releases/fibrobiologics-to-provide-company-update-at-upcoming-conferences-301927271.html  

 

Ho scritto e condiviso questo articolo
Author: Red AdnkronosWebsite: http://ilcentrotirreno.it/Email: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.